What are the guidelines for prescribing topical immunomodulators for the treatment of pediatric atopic dermatitis (AD)?

Updated: Apr 26, 2021
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD  more...
  • Print

At the present time, physicians are advised to use the following guidelines when prescribing topical immunomodulators such as tacrolimus and pimecrolimus [62, 63] :

  • Use in patients older than 2 years

  • Use intermittently as needed, not on a daily basis for prolonged periods (ie, >6 wk)

  • Avoid use in immunocompromised patients or in those with neoplasms

  • Atypical atopic dermatitis, including new onset disease in an adult, should warrant a skin biopsy prior to topical immunomodulator use, to rule out other diagnoses (eg, cutaneous T-cell lymphoma, Netherton syndrome)

  • Encourage sun protection to reduce the risk of photocarcinogenesis

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!